First-In-Human Trial Begins with NOP Agonist for Pain Management
Details : Pre-clinical data show that NOP receptor agonists, a G protein-coupled receptor agoinst, have the potential to act as potent analgesics without abuse liability.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 22, 2024
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Details : A target-based programme progresses into late preclinical development, contributing to pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
Product Name : EVT8683
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
August 08, 2024
Details : BRT-DA01 (bemdaneprocel), is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 28, 2023
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Details : KUR-101 is an atypical opioid receptor modulator with a unique pharmacology that may make it safer for chronic use. Its deuteration improves its pharmacokinetic and overall safety profile while reducing dosing requirements.
Product Name : KUR-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2022
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
Details : The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).
Product Name : Anle138b
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2020
Peripheral NOP Agonist Addressing Chronic Peripheral Neuropathic Pain Enters Clinical Development
Details : The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and mu...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 16, 2020
Details : Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in anima...
Product Name : Anle138b
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 08, 2020